Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.

We currently have four products in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT307 for the treatment of CASQ2-related Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), and AT982 for the treatment of Pompe disease.
Stock Information
BOLD (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.84 (3.16%)
Data as of 09/21/17 4:00 p.m. ET
Refresh quote
Stock chart for: BOLD.O.  Currently trading at $27.41 with a 52 week high of $28.48 and a 52 week low of $13.13.
Recent NewsMore >>
Audentes Therapeutics Announces Dosing of First Patient in ASPIRO, a Phase 1/2 Clinical Trial of AT132 for the Treatment of X-Linked Myotubular Myopathy
Audentes Therapeutics to Present at Upcoming Investor Conferences
Audentes Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
Upcoming EventsMore >>
Wednesday, September 27, 2017 11:30 a.m. ET
Audentes Therapeutics Inc at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology

Tuesday, October 10, 2017 10:45 a.m. ET
Audentes Therapeutics Inc at Chardan Inaugural Gene Therapy Conference

Primary IR Contact
Thomas Soloway
SVP and Chief Financial Officer
Audentes Therapeutics, Inc.
E-mail: ir@audentestx.com

Data provided by Nasdaq. Minimum 15 minutes delayed.